Navigation Links
Kemwell Appoints Dr. Ninad Deshpanday to Head Global R&D
Date:2/14/2013

BANGALORE, February 15, 2013 /PRNewswire/ --

Kemwell Biopharma Pvt. Ltd, a global pharmaceutical contract development and manufacturing company, announced that it has appointed Dr. Ninad Deshpanday as President of Research and Development.

Anurag Bagaria , Chairman and Managing Director of Kemwell said, "Dr. Deshpanday brings a unique combination of leadership skills and technical expertise in pharmaceutical development, as well as excellent business development skills with a very strong network of customers in the US, Europe and Asia. He will spearhead the R&D business for Kemwell as we continue to grow the geographical footprint and strategically position Kemwell into a leading Global Contract Services Provider."

Dr. Deshpanday has over 22 years' experience of diverse international experience in the pharmaceutical industry (US + India). This includes pharmaceutical development activities for NDAs, specialty drug delivery based 505(b)(2) products, including Oral and Transdermal, and complex Generic products, with several F2Fs and PIVs. He also has rich experience in Technical and Business Development

Prior to joining Kemwell, he was President of Pharmaceutical R&D at Lupin, in Pune, India since Nov. 2007, with leadership responsibilities for formulations, analytical, and BA/BE activities. Before joining Lupin, Dr. Deshpanday was Vice President of Business Development at AAIPharma in RTP, NC, with responsibilities for sales and marketing activities for their CM&C functions; Vice President for Drug Product Development for Synta Pharmaceuticals, with responsibilities for all CM&C activities; and Technical Business Director for the Pharmaceutics division of Cardinal Health. Dr. Deshpanday earned his Doctorate in Pharmaceutics from the University of S. Carolina in 1990, and has an M. Pharm. and B. Pharm. from LM College of Pharmacy in Ahmedabad, India.

About Kemwell Biopharma Pvt. Ltd.

Kemwell Biopharma Pvt. Ltd, headquartered in Bangalore, India is a pure-play global contract development and manufacturing company. The company manufactures and develops pharmaceuticals for some of the world's top pharmaceutical companies, including GlaxoSmithKline, Bayer, Novartis and Pfizer. Kemwell is one of India's largest contract manufacturers of pharmaceuticals with over 30 years' experience. The company employs more than 1000 employees worldwide and has seven production facilities, five in India and two in Sweden. Kemwell is an approved pharmaceutical manufacturer in over 80 countries including the American, European, Japanese and Indian markets. Read more about Kemwell on www.kemwellbiopharma.com.

Primary Media Contact: Karan Bagaria , karan.bagaria@kemwellpharma.com, 91-80-39286200

Secondary Media Contact: Bhaskar Viswanathan , bhaskar.viswanathan@kemwellpharma.com, 91-80-39286200


'/>"/>
SOURCE Kemwell Biopharma Pvt Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Avantium Appoints Jonathan Wolfson to its Supervisory Board
2. Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
3. PCI Appoints Jose Solorio-Ruiz, MBA, Manager of West Coast Operations
4. Advanced Cell Diagnostics Appoints Evangeline Gonzalez as Chief Commercial Officer
5. California Healthcare Institute Appoints Allergan CEO Chairman of the Board, Elects New Board Members
6. uniQure Appoints Philip Astley-Sparke President US
7. HealthEconomics.Com Appoints New Director of Information Technology and Operations
8. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
9. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
10. Lakewood-Amedex Inc. Appoints Marie E. Knight To Its Board Of Directors
11. Amarantus Appoints Super Bowl Champion Toi Cook to Board of Advisors to Advance TBI Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... 23, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... Laboratory, has joined STACS DNA as a Field Application Specialist. , “I am ... and COO of STACS DNA. “In further expanding our capacity as a scientific integrator, ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):